share_log

Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target

Benzinga ·  May 6 10:32

Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment